MedTrace Logo

Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori

NCT01667575 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2013-06-04

No results posted yet for this study

Summary

The purpose of this study is to observe the efficacy of ten day triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.

Conditions

  • Functional Dyspepsia
  • Peptic Ulcer
  • Helicobacter Pylori

Interventions

DRUG

Esomeprazole

antisecretary drug of the quadruple therapy

DRUG

Amoxicillin

antibiotic of the quadruple therapy

DRUG

Clarithromycin

antibiotic of the quadruple therapy

DRUG

Bismuth Potassium Citrate

one of a component of a quadruple therapy

OTHER

long duration (14 day)

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Hong Lu, M.D. · Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667575 on ClinicalTrials.gov